ASCO 2024: Rybrevant plus lazertinib bests osimertinib in NSCLC

1 June 2024

US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in patients with high-risk disease or clinical features, which occur in nearly 85% of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.

Results from the new analysis show the amivantamab-combination consistently and significantly improved progression free survival (PFS) compared to osimertinib (AstraZeneca’s Tagrisso) in patients with NSCLC with EGFR exon 19 deletion (ex19del) or L858R mutations.

These data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting now taking place in Chicago.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK